Want to see HK:0719 full AI Analyst Report?
Shandong Xinhua Pharmaceutical Company Limited Class H (0719) AI Stock Analysis
Top Page
Shandong Xinhua Pharmaceutical Company Limited Class H
(HKEX:0719)
The score is driven primarily by mid-quality financial performance: the company remains profitable with manageable leverage and positive cash flow, but TTM revenue and margins have weakened and free cash flow momentum is negative. Technicals further weigh on the rating as the stock trades below key moving averages with negative MACD. Valuation is a modest offset due to the ~3.19% dividend yield, but the high ~36.99 P/E limits upside without a fundamental rebound.
Shandong Xinhua Pharmaceutical Company Limited Class H (0719) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 8.06B
- Dividend Yield
- 3.22%
- Average Volume (3M)
- 1.01M
- Price to Earnings (P/E)
- 37.2
- Beta (1Y)
- 0.60
- Revenue Growth
- -0.52%
- EPS Growth
- -37.60%
- Country
- Hong Kong
- Employees
- 7,240
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Pharmaceuticals
Shandong Xinhua Pharmaceutical Company Limited Class H Business Overview & Revenue Model
Company Description
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. The company offers antipyretic an...
Shandong Xinhua Pharmaceutical Company Limited Class H Financial Statement Overview
Summary
Financials remain profitable with manageable leverage and positive TTM operating/free cash flow, but recent fundamentals have softened: TTM revenue is down ~5% and margins compressed sharply (gross margin ~18% vs ~29% in 2023; net margin ~2.8% vs ~5–6% in 2022–2024). Free cash flow is currently converting well vs net income (~0.79) but has been volatile and fell ~20% in TTM, keeping the score mid-range.
Income Statement
56NeutralBalance Sheet
72PositiveCash Flow
60Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.02B | 8.75B | 8.47B | 8.10B | 7.50B | 6.56B |
| Gross Profit | 1.43B | 1.64B | 2.04B | 2.32B | 2.04B | 1.77B |
| EBITDA | 440.38M | 988.87M | 1.11B | 1.09B | 1.01B | 908.67M |
| Net Income | 227.94M | 289.89M | 470.02M | 496.51M | 411.06M | 348.55M |
Balance Sheet | ||||||
| Total Assets | 8.81B | 9.19B | 9.02B | 8.29B | 8.27B | 7.33B |
| Cash, Cash Equivalents and Short-Term Investments | 1.19B | 1.40B | 1.25B | 918.33M | 1.16B | 744.66M |
| Total Debt | 894.24M | 1.31B | 1.35B | 1.08B | 1.38B | 1.04B |
| Total Liabilities | 3.22B | 3.73B | 3.80B | 3.51B | 3.92B | 3.68B |
| Stockholders Equity | 5.34B | 5.21B | 4.99B | 4.55B | 4.13B | 3.47B |
Cash Flow | ||||||
| Free Cash Flow | 307.79M | 418.13M | 155.19M | -59.85M | 513.48M | 9.89M |
| Operating Cash Flow | 390.87M | 533.73M | 367.61M | 265.28M | 758.24M | 259.12M |
| Investing Cash Flow | -70.46M | -103.50M | -212.21M | -305.11M | -228.90M | -237.69M |
| Financing Cash Flow | -351.09M | -291.13M | 184.78M | -196.11M | -130.66M | -139.73M |
Shandong Xinhua Pharmaceutical Company Limited Class H Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0719, the sentiment is Negative. The current price of 5.35 is below the 20-day moving average (MA) of 5.53, below the 50-day MA of 5.63, and below the 200-day MA of 6.08, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 39.63 is Neutral, neither overbought nor oversold. The STOCH value of 38.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0719.
Shandong Xinhua Pharmaceutical Company Limited Class H Peers Comparison
Overall Rating
HK:168187Outperform
HK:151377Outperform
HK:332068Neutral
HK:087457Neutral
HK:046056Neutral- HK:071956Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1681 | 87Outperform | HKD 12.54B | 9.38 | 25.10% | 5.11% | 15.05% | 20.58% |
| HK:1513 | 77Outperform | HKD 26.72B | 16.30 | 11.32% | 6.71% | -9.56% | -23.22% |
| HK:3320 | 68Neutral | HKD 29.12B | 6.18 | 7.92% | 5.17% | 7.94% | 52.83% |
| HK:0874 | 57Neutral | HKD 35.32B | 14.74 | 5.57% | 6.71% | 6.00% | -23.05% |
| HK:0460 | 56Neutral | HKD 6.76B | 18.42 | 5.03% | 1.50% | 29.68% | ― |
| HK:0719 | 56Neutral | HKD 8.28B | 37.23 | 4.32% | 3.22% | -0.52% | -37.60% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:0719 | Shandong Xinhua Pharmaceutical Company Limited Class H | 5.35 | -1.42 | -20.94% | |
| HK:0874 | Guangzhou Baiyunshan Pharmaceutical Holdings Company Class H | 12.86 | -5.10 | -28.41% | |
| HK:1513 | Livzon Pharmaceutical Group Class H | 23.18 | -5.02 | -17.81% | |
| HK:0460 | Sihuan Pharmaceutical Holdings Group | 0.72 | -0.75 | -50.71% | |
| HK:3320 | China Resources Pharmaceutical Group Ltd. | 4.63 | -0.11 | -2.26% | |
| HK:1681 | Consun Pharmaceutical Group Ltd. | 15.25 | 1.00 | 7.00% |
Shandong Xinhua Pharmaceutical Company Limited Class H Corporate Events
Shandong Xinhua Pharma Posts Lower Nine‑Month Profit Despite Asset Growth
Shandong Xinhua Pharmaceutical Company Limited, a Hong Kong‑listed Chinese drug maker, reports its consolidated results under China Accounting Standards for Business Enterprises and maintains compliance with Hong Kong’s listing and inside...
Xinhua Pharmaceutical’s Nimodipine Tablets Clear China’s Generic Consistency Review
Shandong Xinhua Pharmaceutical announced that its nimodipine tablets have passed China’s generic drug quality and efficacy consistency evaluation, following approval from the National Medical Products Administration. The product, already approv...
Shandong Xinhua Pharma Calls EGM to Approve New Executive Director
Shandong Xinhua Pharmaceutical Company Limited has convened an extraordinary general meeting for 10 November 2026 in Zibo, Shandong Province, to seek shareholder approval for the appointment of Mr. Liu Weimin as an executive director. His proposed te...
Shandong Xinhua Pharmaceutical Sets Board Meeting to Review Nine-Month Results
Shandong Xinhua Pharmaceutical Company Limited has scheduled a board meeting to be held in Zibo, Shandong, on 28 October 2026 at 9:30 a.m. The directors will review and approve the unaudited financial results of the company and its subsidiaries for t...
Shandong Xinhua Pharma Proposes Board Appointment of Senior Economist Liu Weimin
Shandong Xinhua Pharmaceutical Company Limited has proposed the appointment of Mr. Liu Weimin, a 47-year-old senior economist with extensive enterprise management experience at controlling shareholder Hualu Holding Group, as an executive director. Li...
Xinhua Pharmaceutical Wins Approval for Sacubitril Valsartan Tablets in China
Shandong Xinhua Pharmaceutical Company Limited has received a Drug Registration Certificate from China’s National Medical Products Administration for its sacubitril valsartan sodium tablets, a Class 4 chemical prescription drug. The approval co...
Shandong Xinhua Subsidiary Wins Approval for Donepezil Orally Disintegrating Tablets in China
Shandong Xinhua Pharmaceutical announced that its wholly owned subsidiary, Shandong Zibo Xincat Pharmaceutical, has obtained a drug registration certificate from China’s National Medical Products Administration for its 5mg Donepezil Hydrochlori...
Shandong Xinhua Pharmaceutical Wins Approval for New Oral Solution
Shandong Xinhua Pharmaceutical Company Limited has obtained a Drug Registration Certificate from China’s National Medical Products Administration for its magnesium sulfate, sodium sulfate and potassium sulfate concentrate oral solution, classif...
Shandong Xinhua Pharma Wins Approval for Levocarnitine Oral Solution
Shandong Xinhua Pharmaceutical Company Limited, a Chinese producer of chemical prescription drugs, has expanded its product portfolio with a new oral formulation. The company focuses on domestic drug production and compliance with national pharmaceut...
Shandong Xinhua Subsidiary Wins Key Generic Consistency Approval for Azithromycin
Shandong Xinhua Pharmaceutical has announced that its wholly owned subsidiary, Shandong Zibo Xincat Pharmaceutical, received approval from China’s National Medical Products Administration confirming that its azithromycin tablets have passed the...
Shandong Xinhua Wins NMPA Approval for Dapoxetine Tablets
Shandong Xinhua Pharmaceutical has obtained a Drug Registration Certificate from China’s National Medical Products Administration for its domestically produced Dapoxetine Hydrochloride Tablets, a Class 4 chemical prescription drug. The approval...
Shandong Xinhua Pharmaceutical Releases Unaudited 2026 Interim Results
Shandong Xinhua Pharmaceutical Company Limited, a PRC-based drug manufacturer, operates from Zibo City in Shandong Province and is listed on both the Hong Kong and Shenzhen stock exchanges. The company’s dual listing structure in H and A shares...
Xinhua Pharmaceutical Wins China Approval for Dapagliflozin Tablets
Shandong Xinhua Pharmaceutical Company Limited has received a Drug Registration Certificate from China’s National Medical Products Administration for its dapagliflozin tablets. The approval covers domestically produced 5mg and 10mg prescription...
Shandong Xinhua Pharmaceutical Schedules Board Meeting to Review 2026 Interim Results
Shandong Xinhua Pharmaceutical Company Limited has scheduled a board meeting to be held at its conference room in Zibo, Shandong, on 25 August 2026. The meeting will review and approve the unaudited interim results for the six months ended 30 June 20...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 30, 2026